Figures computed from official regulatory filings — .
Analysttarget 32.5 USD (+179%) · consensus 4.5/5 · 2 buy · 0 hold · 0 sell
Ownershipinsiders 0.92% · institutions 37% · short 29.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for SELLAS Life Sciences Group, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
5 buys108 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Einhorn Irving M. | Award | $5.5K | SEC | ||
| Award |
| $5.2K |
| Unusual size |
| SEC |
| Nisi Rudolph | Award | $6.5K | SEC |
| GRAY MARY ANN | Award | $5.9K | SEC |
| Chin Richardtrack record | Award | $4.8K | Unusual size | SEC |
| Ashton William | Award | $5.9K | Unusual size | SEC |
| Hillsberg Sanford | Award | $8K | Unusual size | SEC |
| GRAY MARY ANN | Award | $5.8K | SEC |
| Hillsberg Sanford | Award | $7.9K | Unusual size | SEC |
| Chin Richardtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ashton William | Award | $5.8K | Unusual size | SEC |
| GALLIKER STEPHEN S | Award | $5.2K | Unusual size | SEC |
| Ashton William | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nisi Rudolph | Award | $6.4K | SEC |
| Hillsberg Sanford | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nisi Rudolph | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GALLIKER STEPHEN S | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chin Richardtrack record | Award | $4.8K | Unusual size | SEC |
| GRAY MARY ANN | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Einhorn Irving M. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Einhorn Irving M. | Award | $5.4K | SEC |
| Nisi Rudolph | Sell | $275 | SEC |
| Hillsberg Sanford | Award | $7.9K | Unusual size | SEC |
| Ashton William | Award | $5.8K | Unusual size | SEC |
| GRAY MARY ANN | Award | $5.2K | SEC |